Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models

被引：4
|
作者：
Mosher, Rebecca [1 ]
Poling, Laura [1 ]
Qin, LiuLiang [1 ]
Bodyak, Natalya [1 ]
Bergstrom, Donald [1 ]
机构：
[1] MersanaTherapeutics, Cambridge, MA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-B119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B119
引用
收藏
页数：2
相关论文
共 34 条
  • [1] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
    Hamilton, E. P.
    Barve, M. A.
    Tolcher, A. W.
    Buscema, J.
    Papadopoulos, K. P.
    Zarwan, C.
    Anderson, C. K.
    Doroshow, D.
    Wang, D.
    Huebner, D.
    Jansen, V. M.
    Jarlenski, D.
    Mosher, R.
    Kaufman, J.
    Moore, K. N.
    Richardson, D. L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628
  • [2] The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
    Bodyak, Natalya D.
    Mosher, Rebecca
    Yurkovetskiy, Aleksandr, V
    Yin, Mao
    Bu, Charlie
    Conlon, Patrick R.
    Demady, Damon R.
    DeVit, Michael J.
    Gumerov, Dmitry R.
    Gurijala, Venu R.
    Lee, Winnie
    McGillicuddy, Dennis
    Park, Peter U.
    Poling, Laura L.
    Protopova, Marina
    Qin, LiuLiang
    Stevenson, Cheri A.
    Ter-Ovanesyan, Elena
    Uttard, Alex
    Xiao, Dongmei
    Xu, Jian
    Xu, Ling
    Bergstrom, Donald A.
    Lowinger, Timothy B.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (05) : 896 - 905
  • [3] Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
    Tolcher, Anthony W.
    Ulahannan, Susanna Varkey
    Papadopoulos, Kyriakos P.
    Edenfield, William Jeffery
    Matulonis, Ursula A.
    Burns, Timothy F.
    Mosher, Rebecca
    Fielman, Barbara
    Hailman, Eric
    Burris, Howard A.
    Moore, Kathleen N.
    Hamilton, Erika Paige
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC
    Bergstrom, Donald
    Bodyak, Natalya
    Yurkovetskiy, Alex
    Poling, Laura
    Yin, Mao
    Protopopova, Marina
    Devit, Mike
    Qin, Liuliang
    Gumerov, Dmitry
    Ter-Ovanesyan, Elena
    Mosher, Rebecca
    Lowinger, Timothy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S396 - S397
  • [5] A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation
    Richardson, D. L.
    Hamilton, E.
    Tolcher, A.
    Burns, T. F.
    Edenfield, W. J.
    Papadopoulos, K. P.
    Matulonis, U. A.
    Huebner, D.
    Mosher, R.
    Jarlenski, D.
    Pennock, G.
    Cyr, M.
    Ulahannan, S. V.
    Moore, K. N.
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 159 : 52 - 52
  • [6] Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b
    Huang, Wentao
    Liu, Zhifang
    Li, Yifan
    Pan, Heng
    Qin, Xia
    Fei, Da
    Li, Runsheng
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [7] Preclinical development of NaPi2b-PL2202, a novel camptothecin- based antibody-drug conjugate targeting solid tumors expressing NaPi2b
    Horsley, Elizabeth
    Jabeen, Asma
    Veillard, Nicolas
    Havenith, Karin
    Janghra, Narinder
    Alves, Pedro
    Oblette, Cecile
    Kirby, Ian
    Hogg, Paul W.
    Zammarchi, Francesca
    de Haan, Lolke
    van Berkel, Patrick
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [8] UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
    Hays, John
    Werner, Theresa
    Lakhani, Nehal
    Edenfield, Jeffrey
    Buscema, Joseph
    Burns, Timothy
    Carrington, Cassandra
    Keeton, Erika
    Burger, Robert
    Anderson, Charles
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
  • [9] Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
    Lakhani, Nehal
    Burns, Timothy
    Barve, Minal
    Edenfield, Jeffery
    Hays, John
    Zarwan, Corrine
    Werner, Theresa
    Anderson, Charles
    Buscema, Joseph
    Bernardo, Patricia
    Keeton, Erika
    Carrington, Cassandra
    Burger, Robert
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S285 - S286
  • [10] COMPARISON OF NAPI2B EXPRESSION FROM PAIRED TISSUE SAMPLES IN A CLINICAL STUDY OF UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) SUPPORTS A STRATEGY OF TESTING IN ARCHIVE MATERIAL
    Richardson, Debra
    Barve, Minal
    Saltos, Andreas
    Papadopoulos, Kyriakos
    Hays, John
    Tolcher, Anthony
    Ellard, Susan
    Doroshow, Deborah
    Mitchell, Paul
    Zarwan, Corrine
    Werner, Theresa
    Anderson, Charles
    Spira, Alex
    Mileshkin, Linda
    Bradshaw, Chelsea
    Demars, Leslie
    Mosher, Rebecca
    Hamilton, Erika
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A55 - A56
1234